Raymond James upgraded Cigna to Strong Buy from Outperform with an unchanged price target of $350. Following the stock’s underperformance year-to-date, the analyst is more constructive on the shares. The setup going forward is more favorable as many of the policy overhangs are behind the company and Cigna is well positioned to have a strong 2023, the analyst tells investors in a research note. The firm remains convinced that legislative risks are minimal.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CI:
- Cigna management to meet with Stephens
- Cigna management to meet with Mizuho
- Ohio AG Yost sues Express Scripts, Prime Therapeutics over drug price fixing
- Cigna, Humana accused of price fixing by Ohio attorney general, WSJ reports
- ‘We are heading down’: Leon Cooperman warns that stocks could plunge 22% from here — he’s using these 2 stocks for protection
